Moreover, subjects with CTCL and itching show high IL-31 levels in the circulation and in the skin, and these levels decrease when itching improves during treatment, further highlighting that malignant T cells are the source of IL-31 [65]. This evidence concerns the gene IL31 and primary cutaneous T-cell non-Hodgkin lymphoma.